Roche is out in full force with Tecentriq results in liver cancer. The immuno-oncology med, in combination with fellow Roche drug Avastin, not only showed it could beat Bayer’s standard-of-care Nexavar at stalling...
Latest articles
2019 saw the FDA approve more generic drugs than ever before
Fiscal year 2019 was a record-breaking one, according to the FDA. The US regulator smashed its previous total for annual generic drug approvals with 1,171 positive reviews completed that year, comprising 935 approvals...
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment...
Marketeer zoekt balans inzet off- en online media
Een groot deel van de marketeers wereldwijd (46%) geeft aan nog niet de juiste balans en synergie te hebben gevonden in de inzet van online en offline media. Zo worstelt driekwart (76%) nog steeds met het meten van...
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients. The...
FDA Grants Fast Track Status to FX-322 for Sensorineural Hearing Loss
The Food and Drug Administration (FDA) has granted Fast Track designation to FX-322 (Frequency Therapeutics) for the treatment of sensorineural hearing loss. FX-322 is a combination of proprietary small molecules...
